Levosimendan Kabi (Levosimendan)

Levosimendan is used in the management of acute heart‑failure syndromes and related low‑output states.

• Acute decompensated heart failure: improves cardiac contractility and reduces pulmonary congestion.
• Low cardiac output syndrome: enhances stroke volume and systemic perfusion.
• Heart failure with reduced ejection fraction (HFrEF): provides inotropic support when conventional therapy is insufficient.

• Levosimendan binds to troponin C in cardiac myocytes, increasing the sensitivity of the contractile apparatus to existing intracellular calcium without raising calcium levels. Simultaneously, it opens ATP‑dependent potassium channels in vascular smooth muscle, producing vasodilation and reducing after‑load, thereby improving overall cardiac performance.

Levosimendan may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient drop in blood pressure.
• Nausea: occasional gastrointestinal upset.
• Flushing: warm sensation with skin reddening.
• Tachycardia: increased heart rate.
• Arrhythmia: occasional ectopic beats.

Serious or Rare Side Effects

• Severe hypotension: may require intervention.
• Ventricular arrhythmias: potentially life‑threatening.
• Myocardial ischemia: chest pain or ECG changes.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Liver enzyme elevation: abnormal hepatic function tests.
• Electrolyte disturbances: significant shifts in potassium or magnesium.

Levosimendan should be administered with careful clinical monitoring.

• Cardiovascular monitoring: continuous blood pressure and ECG observation.
• Renal impairment: adjust infusion rate and monitor renal function.
• Hepatic impairment: use with caution in patients with liver disease.
• Electrolyte balance: correct hypokalemia or hypomagnesemia before infusion.
• Concomitant vasodilators: avoid excessive hypotension when combined with nitrates or other vasodilators.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at room temperature: keep in original container, protect from moisture and light.

Levosimendan can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

• Other potent vasodilators (e.g., nitroglycerin): may cause profound hypotension.
• Phosphodiesterase‑5 inhibitors: additive vasodilatory effect.
• Calcium channel blockers: increased risk of cardiovascular depression.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired inotropic response.
• Diuretics: monitor electrolytes and volume status.
• ACE inhibitors/ARBs: watch for additive blood pressure effects.
• Anti‑arrhythmic agents: potential for pro‑arrhythmic events.
• Anticoagulants: monitor for bleeding if hypotension occurs.